UBS Group AG - INVIVO THERAPEUTICS HLDGS CO ownership

INVIVO THERAPEUTICS HLDGS CO's ticker is and the CUSIP is 46186M506. A total of 1 filers reported holding INVIVO THERAPEUTICS HLDGS CO in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
UBS Group AG ownership history of INVIVO THERAPEUTICS HLDGS CO
ValueSharesWeighting
Q1 2022$9,000
+50.0%
25,171
+98.8%
0.00%
Q4 2021$6,00012,659
+43551.7%
0.00%
Q3 2021$0
-100.0%
29
-99.2%
0.00%
Q2 2021$3,000
+50.0%
3,794
+128.3%
0.00%
Q1 2021$2,0001,662
+166100.0%
0.00%
Q4 2020$0
-100.0%
1
-100.0%
0.00%
Q3 2020$9,000
+28.6%
6,303
+52.4%
0.00%
Q2 2020$7,000
+75.0%
4,136
+69.6%
0.00%
Q1 2020$4,0002,4380.00%
Other shareholders
INVIVO THERAPEUTICS HLDGS CO shareholders Q2 2022
NameSharesValueWeighting ↓
WEDBUSH SECURITIES INC 81,491$116,0000.01%
NewSquare Capital LLC 62$00.00%
UBS Group AG 6,303$9,0000.00%
Sugarloaf Wealth Management, LLC 1$00.00%
OSAIC HOLDINGS, INC. 32$00.00%
Jacobi Capital Management LLC 1$00.00%
BANK OF AMERICA CORP /DE/ 39$00.00%
FLAGSHIP HARBOR ADVISORS, LLC 1$00.00%
WELLS FARGO & COMPANY/MN 32$00.00%
NORTHERN TRUST CORP 12,751$18,0000.00%
View complete list of INVIVO THERAPEUTICS HLDGS CO shareholders